BioCardia, Inc.
BCDA
$2.27
$0.136.08%
| Weiss Ratings | BCDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | BCDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | BCDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.46 | |||
| Price History | BCDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -12.69% | |||
| 30-Day Total Return | -9.20% | |||
| 60-Day Total Return | -1.73% | |||
| 90-Day Total Return | 11.82% | |||
| Year to Date Total Return | 0.44% | |||
| 1-Year Total Return | -62.14% | |||
| 2-Year Total Return | -92.43% | |||
| 3-Year Total Return | -93.03% | |||
| 5-Year Total Return | -95.41% | |||
| 52-Week High % Change | -65.83% | |||
| 52-Week Low % Change | 31.69% | |||
| Price | BCDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $6.26 | |||
| 52-Week Low Price | $1.63 | |||
| 52-Week Low Price (Date) | Dec 19, 2024 | |||
| 52-Week High Price (Date) | Apr 02, 2024 | |||
| Valuation | BCDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 10.02M | |||
| Enterprise Value | 8.60M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -3.85 | |||
| Earnings Per Share Growth | -53.58% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 169.84 | |||
| Price/Book (Q) | 11.76 | |||
| Enterprise Value/Revenue (TTM) | 148.19 | |||
| Price | $2.27 | |||
| Enterprise Value/EBITDA (TTM) | -1.08 | |||
| Enterprise Value/EBIT | -1.07 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | BCDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 4.59M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BCDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 650 226 0120 | |||
| Address | 320 Soquel Way Sunnyvale, CA 94085 | |||
| Website | www.biocardia.com | |||
| Country | United States | |||
| Year Founded | -- | |||
| Profitability | BCDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -13,794.82% | |||
| Profit Margin | -13,700.00% | |||
| Management Effectiveness | BCDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -149.03% | |||
| Return on Equity | -- | |||
| Income Statement | BCDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 58.00K | |||
| Total Revenue (TTM) | 58.00K | |||
| Revenue Per Share | $0.01 | |||
| Gross Profit (TTM) | -1.36M | |||
| EBITDA (TTM) | -7.93M | |||
| EBIT (TTM) | -8.00M | |||
| Net Income (TTM) | -7.95M | |||
| Net Income Avl. to Common (TTM) | -7.95M | |||
| Total Revenue Growth (Q YOY) | -100.00% | |||
| Earnings Growth (Q YOY) | -10.81% | |||
| EPS Diluted (TTM) | -3.85 | |||
| EPS Diluted Growth (Q YOY) | 27.27% | |||
| Balance Sheet | BCDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 2.37M | |||
| Cash Per Share (Q) | $0.52 | |||
| Total Current Assets (Q) | 2.62M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 837.00K | |||
| Current Ratio (Q) | 1.130 | |||
| Book Value Per Share (Q) | $0.18 | |||
| Total Assets (Q) | 3.72M | |||
| Total Current Liabilities (Q) | 2.32M | |||
| Total Debt (Q) | 951.00K | |||
| Total Liabilities (Q) | 2.89M | |||
| Total Common Equity (Q) | 837.00K | |||
| Cash Flow | BCDA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -6.00K | |||
| Cash from Financing (TTM) | 9.30M | |||
| Net Change in Cash (TTM) | 1.27M | |||
| Levered Free Cash Flow (TTM) | -8.09M | |||
| Cash from Operations (TTM) | -8.03M | |||
